Jonathan Rios-Doria Email & Phone Number

Wilmington, DE, US

Wilmington, Delaware, United States

• Serve as project lead for monoclonal and bispecific antibody Discovery projects
• Direct in vivo pharmacology plan for 6 preclinical antibody projects, including bispecific and monoclonal antibodies in the Biotherapeutics portfolio.
• Advise management and champion technology development aligned with company strategy to feed early pipeline
• Manage and supervise highly skilled research associates
• Work with CROs to complete time-sensitive studies to support pipeline progression
• Discovery Biology lead for clinical oral PD-L1 programs INCB099280 and INCB099318

Wilmingtom, Delaware

• Directed IND-enabling in vivo pharmacology studies and serve as biology lead for INCB081776, asmall molecule dual inhibitor of AXL and MER kinases, which is currently in Phase I clinical trials
• Designed IND-enabling in vivo pharmacology studies for 3 oral small molecule inhibitors of PD-L1(INCB086550, INCB099280 and INCB099318), which are currently in clinical trials.
• Served as project lead for an IO project and supported in vivo pharmacology for several small molecule Discovery projects
• Demonstrated ability to work cross-functionally and collaboratively
• Support target validation and strategic business development initiatives
• Hired, managed and mentored team of 6 pharmacology associates including PhD-level scientists

Gaithersburg, MD

• Lead in vivo ADC and immunotherapy combination studies in syngeneic mouse models for multiple programs
• Co-lead target validation for multi-specific immuno-oncology drugs using novel technology platforms
• Serve as in vivo pharmacology lead for cancer stem cell antibody therapeutic programs
• Supported in vivo pharmacology and milestone transitions for MEDI9447, an antibody to CD73, which is now in Phase I clinical trials
• Manage team of pharmacology associates and provide mentorship, development and career guidance for associates
• Manage multiple complex research projects, external collaborations, and CRO studies

Gaithersburg, MD

• Manage in vivo pharmacology team of three and provide mentorship, development, and career guidance for associates
• Generated high-quality and high-impact in vivo efficacy, MOA, PK/PD and in vitro data that strongly influenced pipeline progression and achieved critical milestones
• Utilized xenograft, PDX and syngeneic cancer models for evaluating activity of monoclonal antibodies, antibody drug conjugates and immune-mediated therapies for cancer
• Work effectively in matrix environment to achieve program goals and collaborate frequently both within and outside of the department
• Co-led innovative idea that placed in the top 5 in an organization-wide (including AstraZeneca) competition for innovative ideas
• Manage external collaborations and projects with CROs

Tampa, FL

• Manage preclinical study planning and execution and write final report documents for FDA and collaborator distribution.
• Manage in vitro study projects to support efficient and timely in vivo project completion.
• Write patents, grants, and contract proposals

• Established Intezyne’s tissue culture research laboratory from the ground up in a new facility, directed laboratory design and acquired equipment and instrumentation.
• Lead preclinical development of multiple drug-loaded nanoparticles in Intezyne’s pipeline that include formulations of daunorubucin, SN-38, and paclitaxel.
• Supervise, train and mentor biological staff members.
• Develop novel analytical methods/in vitro assays to characterize nanoparticles and translate them into animal studies such as pharmacokinetic, biodistribution, and xenograft experiments.
• Utilized pharmacodynamic markers for anticancer drug-loaded nanoparticle activity in cancer cells to validate nanoparticle delivery.
• Guided experimental design that generated valuable preclinical data which directly attracted >$1 million in financial investments in the company.

• Generated stable Histone GFP-expressing HeLa cells with over 90% GFP positive.
• Developed a novel three-color flow cytometric assay for detection of mitosis and apoptosis in GFP-transfected cells.
• Employed shRNA against proteins in DNA damage pathway to sensitize cancer cells to radiation-induced apoptosis.

• First to identify E-cadherin and Beta-catenin as substrates of calpain protease in prostate and mammary epithelial cells.
• Identified E-cadherin and Beta-catenin proteolytic cleavage products as potential cancer biomarkers in prostate and mammary tumors.

Ph.D., Cellular And Molecular Biology

B.S., Cellular And Molecular Biology